2019– Destiny Pharma issued an announcement, which is summarized as
Destiny Pharma is
pleased to announce that it has appointed MedPharm as its expert partner to
develop new topical formulations of the Company’s novel XF-platform compounds.
These new treatments for dermal and ocular infections are part of its second
clinical programme to address the global problem of anti-microbial resistance
(AMR). MedPharm is a world leading contract provider of topical
and transdermal product design and formulation development services using
sophisticated in vitro models to de-risk development
MedPharm will develop
new formulations containing Destiny Pharma’s XF-platform compounds for the
treatment of a number of topically treated infections, including diabetic foot
ulcers and ophthalmic infections.
Original website Link: